The primary objective of phase 1 is to evaluate the safety and tolerability of A2B530 in patients with NSCLC, CRC, and PANC, and to identify the maximum tolerated dose and recommended phase 2 dose (RP2D). The dose-expansion phase will confirm RP2D and collect biomarker data to further characterize A2B530.
8 months ago
CAR T-Cell Therapy • P1/2 data • Clinical • IO biomarker
|
HLA-A (Major Histocompatibility Complex, Class I, A) • CEACAM5 (CEA Cell Adhesion Molecule 5)
BASECAMP-1 is an ongoing prescreening study to: 1) Identify patients with tumor-associated HLA LOH and eligible for Tmod CAR T-cell therapy, and 2) Obtain leukapheresis in preparation for the autologous CAR T-cell therapy trials EVEREST-1 (A2B530 targeting carcinoembryonic antigen; NCT05736731) and EVEREST-2 (A2B694 targeting mesothelin). We have identified 52 patients across sites with study-specific disease types with HLA-A*02:01 LOH; of these, 13 are currently being screened, 23 have been found ineligible, and 16 have consented. This demonstrated the feasibility of leveraging a diagnostic during routine clinical workup to identify rare, molecularly defined patients for personalized clinical studies.
8 months ago
CAR T-Cell Therapy • Clinical • Metastases
|
HLA-A (Major Histocompatibility Complex, Class I, A) • MSLN (Mesothelin) • CEACAM5 (CEA Cell Adhesion Molecule 5)
Thus, the therapeutic effect of CAR-T therapy was related to the target antigen expression level, and the further retrospective analysis of pathological findings from PDAC patients showed a correlation between the intensity of CEA immunostaining and tumor heterogeneity. Therefore, CEA expression levels in biopsies or surgical specimens can be clinically used as biomarkers to select PDAC patients for anti-CAR-T therapy.
1 year ago
Preclinical • Journal • CAR T-Cell Therapy • IO biomarker
BASECAMP-1 ( NCT04981119 ), an observational study identifying patients with somatic HLA LOH, is recruiting. Eligible patients with metastatic colorectal, pancreatic, or non-small cell lung cancer will be apheresed for a future A2B530 EVEREST-1 interventional study.
over 1 year ago
IO biomarker
|
HLA-A (Major Histocompatibility Complex, Class I, A) • CEACAM5 (CEA Cell Adhesion Molecule 5) • LILRB1 (Leukocyte Immunoglobulin Like Receptor B1)